European drug regulators abruptly reverse course on boosters
By Alex Berenson | January 11, 2022
This should terrify you if you’ve received an mRNA booster.
Last month, the European Medicines Agency authorized boosters EVERY THREE MONTHS:

Today, not even five weeks later, and barely 24 hours after Pfizer’s CEO downplayed a fourth dose, they said they think frequent boosters may not be safe:

What changed? What data have they seen since Dec. 9? Animal studies? Side effect reports? Epidemiological data? Or is this just an abundance of caution – caution that did not exist last month?
The time for obfuscation and deception is over. Hundreds of millions of people across the United States and Europe have received mRNA boosters.
They deserve to know the truth.
January 11, 2022 Posted by aletho | Science and Pseudo-Science, Timeless or most popular, War Crimes | COVID-19 Vaccine, European Medicines Agency, European Union | Leave a comment
Why Opening Up Clinical Trials Data Is Good For Pharma Companies Too
By Glyn Moody | Techdirt | November 5, 2013
Earlier this year we wrote about how AbbVie, the pharma company spun out of Abbott Laboratories, had gone to court to stop the European Medicines Agency (EMA) from releasing clinical trials information about one of its drugs. Despite what AbbVie claimed, this was not commercially sensitive in any way, but simply basic data about safety and efficacy.
It’s often overlooked that this data is mostly obtained by testing new drugs on volunteer members of the public who take the medicines in order to establish their safety. By definition, these volunteers are putting themselves at risk. They selflessly offer to do that in order to advance medicine and confer benefits on society as a whole. That means the clinical data obtained from such tests belongs to the public that made them possible, at least from a moral viewpoint.
If a company seeks to prevent the free dissemination of that safety data, as AbbVie is doing in Europe, it is breaking the implicit compact it made with the people who agreed to try out its drugs. Those invited to take part in future trials of AbbVie’s drugs might then begin to ask why they should endanger their health and even lives purely to boost one company’s profits.
But even if AbbVie is resistant to the argument that it has a moral obligation to allow the clinical trials data to be released, and is not concerned that the public might think that it has something to hide, perhaps it will be won over by a recent article in The New England Journal of Medicine, written by four people from the EMA. This puts forward a quite different argument, that releasing test data will directly benefit pharma companies themselves, and offers a number of reasons why.
First, access to the full data sets of completed studies will lead to improvements in the design and analysis of subsequent trials.
Basically, the more information that drug companies have about what works and what doesn’t, the better they can design their future tests.
Second, lessons from past trials about the heterogeneity of treatment effects not only will streamline drug development but also may enhance a drug’s value in the marketplace. Identification of a population with high unmet need in which a new treatment may be more cost-effective than other available treatments can aid sponsors during reimbursement negotiations.
Again, the more information companies have about how different groups of patients responded to a drug, the easier it will be to spot particular sub-groups in the population who derive particular benefit. Selling products for that sub-group will be both easier, more profitable and more ethical than simply trying to sell to everybody, since the drug may be ineffective or even inappropriate for many of the general population.
Third, since several possible treatments for one medical condition are often available, comparative-effectiveness information is important to patients, prescribers, and sponsors seeking to position their products.
For a given condition, there may be several possible treatments. Making clinical test data available allows them to be compared, and the best one selected for future drug development, instead of investing huge sums in what may well be a relatively ineffective approach.
Finally, one of the inherent inefficiencies of data secrecy is the repetition of trials and projects that are doomed from the outset; drug developers may continue to pursue a given target even though clinical trials conducted by others have demonstrated the effort’s futility.
In many ways this is the most important reason. If the results of clinical trials are kept secret, companies run the risk of repeating the mistakes already made by others. Not only is that a waste of time and money that could be better spent on more fruitful avenues, it is putting test subjects at risk unnecessarily. As the NEJM points out:
In at least one documented case, the availability of data from completed trials could have spared trial subjects a potential health risk and saved millions of research dollars.
The article concludes:
A managed-release environment that allows sharing of patient-level data while ensuring patient privacy would create a level playing field for all stakeholders. What is sometimes labeled as “free riding” may ultimately pay dividends for innovative companies and for public health. It is ironic that the organizations that most resist wider access to data are the ones that stand to benefit so much from greater transparency.
In fact, this is no mere theoretical possibility. We know this approach works, because it is precisely what we see in the field of open source. Sharing the code freely creates a level playing-field that allows companies to innovate faster because they can build on the work of others. The rise of a multi-billion dollar software industry based around such sharing, and the unprecedented rate of innovation this drives, are yet more reasons that companies like AbbVie should be striving to promote, not prevent, the release and dissemination of clinical trials information as open data.
Follow me @glynmoody on Twitter
November 5, 2013 Posted by aletho | Economics, Timeless or most popular | AbbVie, Biotechnology and Pharmaceuticals, European Medicines Agency, Pharmaceutical industry | Leave a comment
Featured Video
10 Climate Myths Busted (in 60 seconds!)
or go to
Aletho News Archives – Video-Images
Book Review
How the U.S. Navy Sold the Vietnam War
By Gareth Porter | TruthDig | March 27, 2019
Dr. Tom Dooley, whose best-selling book “Deliver Us From Evil” helped create a favorable climate of opinion for U.S. intervention in South Vietnam, has long been linked to legendary CIA officer Edward G. Lansdale and his black operations in Vietnam between 1954 and 1955. But the real story about Dooley’s influential book, which has finally emerged from more recent scholarly research, is that it was engineered by an official of the U.S. Navy’s Pacific Command, Capt. William Lederer.
Lederer is best known as the co-author, with Eugene Burdick, of the 1958 novel “The Ugly American,” which was turned into a 1963 movie starring Marlon Brando. Far more important, however, is the fact that from 1951 through 1957 Capt. Lederer was on the staff of the commander in chief of the U.S. Pacific Fleet (CINCPAC), Adm. Felix Stump. … continue
Blog Roll
-
Join 2,370 other subscribers
Visits Since December 2009
- 7,822,395 hits
Looking for something?
Archives
Calendar
Categories
Aletho News Civil Liberties Corruption Deception Economics Environmentalism Ethnic Cleansing, Racism, Zionism Fake News False Flag Terrorism Full Spectrum Dominance Illegal Occupation Mainstream Media, Warmongering Malthusian Ideology, Phony Scarcity Militarism Progressive Hypocrite Russophobia Science and Pseudo-Science Solidarity and Activism Subjugation - Torture Supremacism, Social Darwinism Timeless or most popular Video War Crimes Wars for IsraelTags
Afghanistan Africa AIPAC al-Qaeda Australia BBC Benjamin Netanyahu Brazil Canada CDC Central Intelligence Agency China CIA CNN Covid-19 COVID-19 Vaccine Donald Trump Egypt European Union Facebook FBI FDA France Gaza Germany Google Hamas Hebron Hezbollah Hillary Clinton Human rights Hungary India Iran Iraq ISIS Israel Israeli settlement Japan Jerusalem Joe Biden Korea Latin America Lebanon Libya Middle East National Security Agency NATO New York Times North Korea NSA Obama Pakistan Palestine Poland Qatar Russia Sanctions against Iran Saudi Arabia Syria The Guardian Turkiye Twitter UAE UK Ukraine United Nations United States USA Venezuela Washington Post West Bank WHO Yemen Zionism
Aletho News- In Mexico, the CIA Is Playing a Dangerous Game
- Spain’s Left Protested the Crisis It Legitimized: the General Strike as election stunt
- The power of inflicting oblivion
- The 10 Disease Renamings That Rescued the Vaccine
- NATO cancels 2027 leaders’ summit
- IAEA’s politicized use of safeguards undermines its impartiality: Russian envoy
- UK must be ready to strike Russian Arctic – ex-PM
- Fico’s Two Red Lines: Russian Energy and the Next Ukraine Loan
- Thousands rally for banned NATO-skeptic presidential candidate
- Ukraine Settlement and New European Security Architecture Must Go Hand in Hand – Kremlin
If Americans Knew- An error has occurred; the feed is probably down. Try again later.
No Tricks Zone- New Study: Barents Sea Temperatures Were Warmer And Sea Ice Less Extensive In The 1700s Than Today
- German Authorities Start Initiative To Evaluate Public Register For Climate “Disinformation” Spreaders!
- Zonal Asymmetry of Temperature Change in the Antarctic Circumpolar Current
- New Study: The Net Fossil Fuel Contribution To Rising Atmospheric CO2 Has Been Zero For 500 Years
- Germany’s Green Energy Transition Becoming Increasingly Expensive…Another 6 Trillion Euros!
- Sudden Stratospheric Warming, Powerful El Niño Combination May Lead To Extreme Europe Cold, Energy Crisis!
- Two New Studies Find Thwaites Glacier Melt Cannot Be Driven By Human Activity Or A Warming Ocean
- E-Cars Reduce CO2 Emissions By Only 41% Compared To Internal Combustion Engine Vehicles
- Predictions Made By Renowned Climate Professor Over Past Decades Have Been Proven To Be Poor
- New Study Suggests Large Regions Of The Pacific Ocean Have Been Cooling For The Last 80 Years
Contact:
atheonews (at) gmail.com
Disclaimer
This site is provided as a research and reference tool. Although we make every reasonable effort to ensure that the information and data provided at this site are useful, accurate, and current, we cannot guarantee that the information and data provided here will be error-free. By using this site, you assume all responsibility for and risk arising from your use of and reliance upon the contents of this site.
This site and the information available through it do not, and are not intended to constitute legal advice. Should you require legal advice, you should consult your own attorney.
Nothing within this site or linked to by this site constitutes investment advice or medical advice.
Materials accessible from or added to this site by third parties, such as comments posted, are strictly the responsibility of the third party who added such materials or made them accessible and we neither endorse nor undertake to control, monitor, edit or assume responsibility for any such third-party material.
The posting of stories, commentaries, reports, documents and links (embedded or otherwise) on this site does not in any way, shape or form, implied or otherwise, necessarily express or suggest endorsement or support of any of such posted material or parts therein.
The word “alleged” is deemed to occur before the word “fraud.” Since the rule of law still applies. To peasants, at least.
Fair Use
This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more info go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.
DMCA Contact
This is information for anyone that wishes to challenge our “fair use” of copyrighted material.
If you are a legal copyright holder or a designated agent for such and you believe that content residing on or accessible through our website infringes a copyright and falls outside the boundaries of “Fair Use”, please send a notice of infringement by contacting atheonews@gmail.com.
We will respond and take necessary action immediately.
If notice is given of an alleged copyright violation we will act expeditiously to remove or disable access to the material(s) in question.
All 3rd party material posted on this website is copyright the respective owners / authors. Aletho News makes no claim of copyright on such material.